Vandetanib in a Child Affected by Neurofibromatosis Type 1 and Medullary Thyroid Carcinoma with Both NF1 and Homozygous RET Proto-oncogen Germ-line Mutations

Vandetanib in a Child Affected by Neurofibromatosis Type 1 and Medullary Thyroid Carcinoma with Both NF1 and Homozygous RET Proto-oncogen Germ-line Mutations

Blog Article

Cases of neurofibromatosis type 1 (NF1)-associated medullary thyroid carcinoma (MTC) or C-cell hyperplasia are rarely associated with nyx 22 brush other endocrine tumors or cases with a multiple endocrine neoplasia type 2.In these patients, mutations were detected in the NF1 gene but no mutations were detected in the RET gene.Although vandetanib has been shown to improve progression-free survival in adults with advanced MTC, data in pediatric patients are limited.Herein, we report the use and outcome of vandetanib in a pediatric MTC case in which here NF1 gene and RET proto-oncogen mutation were identified together.